Investors knew ahead of the Nov. 6 arrival of Puma Biotechnology's (NASDAQ:PBYI) third-quarter update that the report was going to be an important one. The question on everyone's mind was pretty straightforward: Had the company been able to do anything to address physicians' waning enthusiasm for its only drug product?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,